Processing...
Clinical Trials for Head And Neck Cancer
Search
Search
There are 211 active trials for advanced/metastatic head and neck cancer.
Click on a trial to see more information.
211 trials meet filter criteria.
Sort by:
TrialFetch AI summary: Patients with unresectable locally advanced or metastatic solid tumors harboring eligible AKT/PI3K/PTEN pathway alterations receive the investigational oral selective AKT1 inhibitor TER-2013 alone. Patients with HR-positive/HER2-negative advanced breast cancer previously treated with an aromatase inhibitor may receive TER-2013 with fulvestrant.
ClinicalTrials.gov ID: NCT07109726
TrialFetch AI summary: Adults with measurable metastatic melanoma, colorectal cancer, pancreatic ductal adenocarcinoma, or head and neck squamous cell carcinoma harboring selected MAPK-pathway mutations, ECOG 0–1, and no suitable standard therapy receive oral IPN01194 monotherapy. IPN01194 inhibits ERK1/2, downstream components of MAPK signaling.
ClinicalTrials.gov ID: NCT06305247
TrialFetch AI summary: Adults under 70 with metastatic gastrointestinal cancer that has progressed after standard chemotherapy, or who are ineligible for it, and an injectable tumor receive a single intratumoral injection of vvDD-hIL-2-RG-1. This oncolytic vaccinia virus is engineered for tumor-selective activity and expression of membrane-bound human IL-2 to stimulate antitumor T-cell responses.
ClinicalTrials.gov ID: NCT07001592
TrialFetch AI summary: Adults with metastatic or unresectable HER2‑negative adenocarcinoma of the esophagus/GEJ/stomach (no prior metastatic therapy; ECOG 0–2) receive an alternating doublet sFOLFOXIRI schedule: mFOLFOX6 on odd cycles and FOLFIRI on even cycles every 2 weeks. Optional nivolumab (PD‑1 inhibitor) may be added per label to enhance antitumor activity.
ClinicalTrials.gov ID: NCT05332002
TrialFetch AI summary: Adults with measurable, locally advanced or metastatic solid tumors that have progressed after prior therapy and lack suitable treatment options receive intravenous SPX-303 every 3 weeks in dose-escalation and expansion cohorts. SPX-303 is an investigational bispecific antibody targeting LILRB2 on myeloid cells and PD-L1 to counter tumor-associated immune suppression.
ClinicalTrials.gov ID: NCT06259552
TrialFetch AI summary: Adults with measurable recurrent or metastatic head and neck squamous cell carcinoma who have not received systemic therapy for recurrent or metastatic disease and are candidates for pembrolizumab monotherapy are randomized to pembrolizumab alone or with BI 770371, with or without cetuximab. BI 770371 blocks the SIRPα–CD47 interaction to promote immune-cell engulfment of tumor cells; cetuximab inhibits EGFR signaling.
ClinicalTrials.gov ID: NCT06806852
TrialFetch AI summary: Adults with measurable, unresectable locally advanced or metastatic NSCLC, head and neck squamous cell carcinoma, or melanoma may be eligible if they are checkpoint inhibitor–naive or have progressed after anti-PD-(L)1 therapy; additional PD-L1 criteria apply to checkpoint inhibitor–naive NSCLC and head and neck cancer. Treatment combines pembrolizumab with oral CJRB-101, an investigational live biotherapeutic containing Leuconostoc mesenteroides that aims to modulate gut microbiome–associated antitumor immunity.
ClinicalTrials.gov ID: NCT05877430
TrialFetch AI summary: Adults with recurrent/metastatic, incurable HNSCC (oral cavity, oropharynx, hypopharynx, larynx, or cervical node with occult primary) who are chemo‑naïve in the R/M setting and not candidates for infusional 5‑FU receive pembrolizumab (anti–PD‑1) plus weekly carboplatin/paclitaxel for six cycles, then pembrolizumab maintenance. Key exclusions include untreated symptomatic CNS mets, active autoimmune disease needing immunosuppression, prior severe hypersensitivity to carboplatin/paclitaxel, and significant uncontrolled comorbidities.
ClinicalTrials.gov ID: NCT04858269
TrialFetch AI summary: Adults with measurable, locally advanced or metastatic bladder cancer or squamous cell carcinoma of the lung, esophagus, skin, or anogenital region, generally after standard therapy, receive EVOLVE104 monotherapy. This investigational trispecific T-cell engager binds tumor-cell ULBP2/5/6 and T-cell CD3 and CD2 to promote T-cell killing with CD2 costimulation.
ClinicalTrials.gov ID: NCT07217171
TrialFetch AI summary: Patients with incurable locally advanced, recurrent, or metastatic solid tumors who lack appropriate standard treatment receive once-daily oral CP-383, an investigational dual DHODH/TEAD4 inhibitor. Dose expansion focuses on selected cancers, including colorectal, small-cell lung, and head and neck cancers, with some cohorts defined by tumor alterations.
ClinicalTrials.gov ID: NCT07030257